Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity ...

Back in 2023, Honda America Vice President, Jay Joseph said: “The concept is simple: We will no longer have to dig holes in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TOKYO -- Japan's Mitsubishi Chemical Group has granted a first-refusal right to U.S. investment fund Bain Capital for the purchase of its pharmaceutical subsidiary Mitsubishi Tanabe Pharma ...

Mitsubishi Chemical Group is stepping up its efforts to streamline operations by entering negotiations with U.S. investment fund Bain Capital to sell its pharmaceutical arm, Mitsubishi Tanabe Pharma.

Mitsubishi Chemical Corporation had considered building the plant as early as 2016, but ultimately abandoned plans earlier this month after finding that demand wasn’t high enough to warrant the ...

Mitsubishi is developing a new Pajero Sport, the current generation of which is sold as the Montero Sport in some markets Sales of the midsize SUV are expected to start in 2026, though a U.S ...